---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-001767"
form_type: "8-K"
ticker: "BLFS"
cik: "0000834365"
company_name: "BIOLIFE SOLUTIONS INC"
filed_at: "2026-01-12T23:59:59+00:00"
generated_at: "2026-05-16T10:59:43.535380+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# BioLife Solutions reports preliminary Q4 2025 revenue $24.8M (+20% YoY); FY 2025 revenue $96.2M beats raised guidance

## Summary
- Q4 2025 continuing ops revenue $24.8M, up 20% from $20.7M in Q4 2024.
- FY 2025 revenue $96.2M, up 29% from $74.6M in 2024, exceeding raised guidance of $95-96M.
- Q4 revenue excludes ~$1.3M in biopreservation revenue shifted to Q3 at customer request.
- CEO notes evo divestiture complete; company now pure-play cell processing with recurring revenue.
- Expects 2026 revenue growth and adjusted EBITDA margin expansion; full guidance in Feb.

## SEC filing metadata
- accession: 0001628280-26-001767
- form_type: 8-K
- ticker: BLFS
- cik: 0000834365
- company_name: BIOLIFE SOLUTIONS INC
- filed_at: 2026-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/834365/000162828026001767/0001628280-26-001767-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/834365/000162828026001767/blfs-20260112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-001767
- JSON: https://secwatch.observer/filing/0001628280-26-001767.json
- Plain text: https://secwatch.observer/filing/0001628280-26-001767.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.